GlassScriptPhysician profile
Christopher Bachuss
NPI 1437147626
$13,382.52
in general payments reported to CMS, 2019-2025
57 companies · $2,784 in 2025
The $2,784 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,294 · 2022: $2,279 · 2023: $3,188 · 2024: $2,838 · 2025: $2,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,801 · Education: $8.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,801.47 |
| Education | $8.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,678.20 | 2021-2025 | |
| Biogen, INC. | $782.53 | 2021-2025 | Vumerity, Tysabri, Plegridy |
| Ucb, INC. | $756.69 | 2021-2025 | Briviact, Zilbrysq, Rystiggo |
| Emd Serono, INC. | $754.77 | 2021-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $714.94 | 2021-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $659.37 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Teva Pharmaceuticals USA, INC. | $643.88 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Acadia Pharmaceuticals INC | $518.19 | 2021-2025 | Nuplazid |
| Tg Therapeutics, INC. | $513.91 | 2023-2025 | |
| Lundbeck LLC | $494.68 | 2022-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $494.49 | 2021-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $467.28 | 2021-2025 | |
| Pfizer INC. | $297.05 | 2021-2025 | |
| Upsher-Smith Laboratories LLC | $274.16 | 2021-2022 | |
| Sk Life Science, INC. | $254.44 | 2021-2025 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $250.67 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $244.36 | 2021-2023 | Ponvory |
| Argenx US, INC. | $229.74 | 2023-2025 | Vyvgart Hytrulo |
| Jazz Pharmaceuticals INC. | $208.91 | 2021-2025 | |
| Mdd US Operations, LLC | $194.38 | 2021-2025 | Gocovri, Apokyn |
| Avanir Pharmaceuticals, INC. | $185.82 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $168.59 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $165.50 | 2023-2025 | Rexulti, Nuedexta |
| Neurelis, INC. | $154.57 | 2021-2025 | Valtoco |
| Amgen INC. | $151.04 | 2021-2025 | Uplizna, Aimovig |
| Biohaven Pharmaceuticals, INC. | $146.72 | 2021 | |
| Banner Life Sciences, LLC | $140.36 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $139.92 | 2023-2024 | Aptiom |
| Horizon Therapeutics Plc | $137.08 | 2021-2023 | Uplizna |
| Avion Pharmaceuticals | $134.93 | 2022 | |
| Csl Behring | $124.06 | 2021-2023 | Hizentra |
| Catalyst Pharmaceuticals, INC. | $120.98 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $116.60 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $93.20 | 2023 | Trudhesa |
| Kyowa Kirin, INC. | $86.78 | 2021-2024 | Nourianz |
| Scilex Pharmaceuticals INC. | $78.45 | 2023-2025 | Ztlido |
| Tanabe Pharma America, INC. | $63.53 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $62.55 | 2023-2024 | Quviviq |
| Octapharma USA, INC. | $61.87 | 2023-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Supernus Pharmaceuticals, INC. | $60.53 | 2022 | |
| Grifols USA, LLC | $55.60 | 2023-2024 | Gamunex-C |
| Amneal Pharmaceuticals LLC | $50.52 | 2024-2025 | Crexont, Rytary |
| Boston Scientific Corporation | $50.18 | 2024-2025 | Vercise, General - Dbs |
| Merck Sharp & Dohme LLC | $49.22 | 2021-2022 | |
| Axsome Therapeutics, INC. | $42.94 | 2025 | Symbravo |
| C2n Diagnostics, LLC | $39.65 | 2025 | Precivityad2 |
| Currax Pharmaceuticals LLC | $39.07 | 2021-2023 | Onzetra Xsail |
| Azurity Pharmaceuticals, INC. | $34.32 | 2023-2024 | Horizant, Horizant |
| Ani Pharmaceuticals, INC. | $31.28 | 2022 | |
| Adamas Pharmaceuticals, INC. | $30.30 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $28.91 | 2021 | |
| Impel Pharmaceuticals LLC | $22.09 | 2025 | Trudhesa |
| Vanda Pharmaceuticals INC. | $20.41 | 2024 | Ponvory |
| Mallinckrodt Hospital Products INC. | $17.36 | 2022 | |
| Cycle Pharmaceuticals INC | $16.98 | 2025 | Bafiertam |
| Celgene Corporation | $14.62 | 2024 | Zeposia |
| Nevro Corp. | $13.35 | 2024 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bachuss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.